Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3916 AL 3930

Exploring the potential of marine microbes in clinical management of Alzheimer's disease: A road map for bioprospecting and identifying promising isolates

Muralidharan A, Josyula VR, Hariharapura RC.

Life Sci. 2018 Sep 1;208:149-160. doi: 10.1016/j.lfs.2018.07.036. Epub 2018 Jul 19.

Alzheimer's Disease: Advances in Drug Development

Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A.

J Alzheimers Dis. 2018;65(1):3-13. doi: 10.3233/JAD-180145.

Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?

Raikwar SP, Thangavel R, Dubova I, Ahmed ME, Selvakumar PG, Kempuraj D, Zaheer S, Iyer S, Zaheer A.

J Alzheimers Dis. 2018;65(2):321-344. doi: 10.3233/JAD-180422.

Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis

Cheng YC, Huang YC, Liu HC.

Dement Geriatr Cogn Disord. 2018;45(5-6):335-352. doi: 10.1159/000490175. Epub 2018 Jul 24.

Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Blanco-Silvente L, Capellà D, Garre-Olmo J, Vilalta-Franch J, Castells X.

BMC Geriatr. 2018 Jul 24;18(1):168. doi: 10.1186/s12877-018-0857-5.

Natural product-based multitargeted ligands for Alzheimer's disease treatment?

Tzvetkov NT, Atanasov AG.

Future Med Chem. 2018 Aug;10(15):1745-1748. doi: 10.4155/fmc-2018-0146. Epub 2018 Jul 25.

Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies

Lon HK, Mendonca N, Goss S, Othman AA, Locke C, Jin Z, Rendenbach-Mueller B.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):290-303. doi: 10.1002/cpdd.598. Epub 2018 Jul 27.

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease

Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC.

CNS Neurosci Ther. 2018 Oct;24(10):876-888. doi: 10.1111/cns.13035. Epub 2018 Jul 29.

Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer's disease dispensed by the Brazilian public health system - 2008 to 2014: a nation-wide analysis

Moraes FS, Souza MLC, Lucchetti G, Lucchetti ALG.

Arq Neuropsiquiatr. 2018 Jul;76(7):444-451. doi: 10.1590/0004-282X20180064.

Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus

Kales HC, Lyketsos CG, Miller EM, Ballard C.

Int Psychogeriatr. 2019 Jan;31(1):83-90. doi: 10.1017/S1041610218000534. Epub 2018 Aug 2.

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M.

CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0.

A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer's Disease

Ajith TA.

Curr Clin Pharmacol. 2018;13(4):252-260. doi: 10.2174/1574884713666180807145648.

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study

Colombo D, Caltagirone C, Padovani A, Sorbi S, Spalletta G, Simoni L, Ori A, Zagni E.

J Womens Health (Larchmt). 2018 Nov;27(11):1368-1377. doi: 10.1089/jwh.2017.6420. Epub 2018 Sep 8.

Psychosocial interventions for Alzheimer's disease cognitive symptoms: a Bayesian network meta-analysis

Duan Y, Lu L, Chen J, Wu C, Liang J, Zheng Y, Wu J, Rong P, Tang C.

BMC Geriatr. 2018 Aug 7;18(1):175. doi: 10.1186/s12877-018-0864-6.

Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease

Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL.

Behav Brain Res. 2019 Jan 1;356:271-278. doi: 10.1016/j.bbr.2018.08.006. Epub 2018 Aug 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias